GLP-1
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, provided an update on the progress of the development of odevixibat for pediatric cholestatic liver diseases and elobixibat for NASH.
Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH
Companies from across the globe provide information on agreements and pipeline updates.
Contract research organization jobs may not seem as appealing as working in R&D but it can have a lot of advantages—including plenty of career opportunities.
Galapagos NV announces a share capital increase arising from warrant exercises.
The approval marks the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for children and adolescents with type 2 diabetes.
Galapagos NV received a transparency notification from The Capital Group Companies, Inc.
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association’s 79th Scientific Sessions in San Francisco this week.
Servier and Galapagos NV completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule.
PRESS RELEASES